3D SYSTEMS CORP
For the period ended Dec 31, 2023. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Aug 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
Director Compensation
We use a combination of cash and equity-based compensation to attract and retain qualified candidates to serve on our Board of Directors. In setting director compensation, we consider the significant amount of time that our directors expend in fulfilling their duties, the skill level required by us of members of our Board, and the overall level and mix of compensation compared to industry- and size-relevant peers by referencing data compiled by the Compensation Committee’s independent compensation consultant.
Director Compensation for 2023
The following table sets forth information concerning all compensation of each of our non-employee directors for their services as a director during the year ended December 31, 2023.
| Name | Fee Earned or Paid in Cash | Stock Awards (1) | All Other Compensation | Total |
|---|---|---|---|---|
| Malissia Clinton | $90,000 | $150,000 | $— | $240,000 |
| William E. Curran | 105,000 | 150,000 | — | 255,000 |
| Claudia N. Drayton | 68,113 | 150,000 | — | 218,113 |
| Thomas W. Erickson | 78,764 | 150,000 | — | 228,764 |
| Jim D. Kever | 70,000 | 150,000 | — | 220,000 |
| Charles G. McClure, Jr. | 250,000 | 150,000 | — | 400,000 |
| Kevin S. Moore | 95,000 | 150,000 | — | 245,000 |
| Vasant Padmanabhan | 66,236 | 150,000 | — | 216,236 |
| John J. Tracy | 90,000 | 150,000 | — | 240,000 |
(1) Represents the aggregate grant date fair value of the stock awards granted in 2023 to each non-employee director computed in accordance with stock-based compensation accounting rules (Financial Standards Accounting Board (“FASB”) ASC Topic 718). The amounts in this column reflect the award of 18,094 shares of Common Stock made to each director in office as their annual equity award under the 2015 Incentive Plan on May 16, 2023. The value of the restricted stock awards was determined by multiplying the number of shares awarded by the closing price of our Common Stock on the date of grant ($8.29 per share).
Director Fees
Director compensation is set by the Board, based upon the recommendation of the Corporate Governance and Sustainability Committee through the periodic review and approval of the Non-Employee Director Compensation Policy. We pay the following cash compensation to our non-employee directors:
| Annual Retainers to Non-Employee Directors | Chair | Member |
|---|---|---|
| Board of Directors(1) | $250,000 | $50,000 |
| Audit Committee | 30,000 | 15,000 |
| Compensation Committee | 30,000 | 15,000 |
| Compliance Committee | 20,000 | 10,000 |
| Corporate Governance and Sustainability Committee | 10,000 | 5,000 |
| Technology Applications Committee | 30,000 | 10,000 |
(1) The Chair of the Board of Directors does not receive fees for service on any committee.
Non-employee directors also receive annual equity awards. We also reimburse directors for their expenses of attendance at meetings of the Board of Directors or its committees.
Dr. Graves, who is an employee of the Company, received no additional compensation for service as a director in 2023.
Director Equity Awards
Pursuant to the Non-Employee Director Compensation Policy, our directors receive annual grants of immediately vested stock equal to $150,000 in total value under the 2015 Incentive Plan upon their re-election by stockholders to serve as directors. In addition, new directors, upon their election to the Board, receive an immediately vested restricted stock award equal to such number of shares having a value equal to $75,000 and a prorated annual award for the year in which he or she is elected to the Board. All shares of Common Stock issued to directors as compensation for their services as directors are fully vested when issued.
Stock Ownership and Holding Requirements for Non-Employee Directors
Consistent with the Board-adopted Qualifications for Nomination to the Board (publicly disclosed as Addendum A to the Corporate Governance and Sustainability Committee Charter), each non-employee director is expected to hold during his or her term of office a meaningful number of shares of Common Stock. As such, our Corporate Governance Guidelines require our non-employee directors to acquire and maintain an equity stake in the Company with a minimum value equivalent to five times the annual cash retainer paid to non-employee directors (as set forth in the Non-Employee Director Compensation Policy) by the later of 2025 or within 5 years of joining the Board.
Each of our non-employee directors are required to retain all shares of Common Stock that have been awarded to them under the 2015 Incentive Plan until the minimum holding requirement is met; however, they may sell up to 50% of the shares of Common Stock covered by any award to satisfy any tax obligation arising from such grant or grants. In addition, non-employee directors are required to retain all shares of Common Stock that were awarded to them under the 2004 Restricted Stock Plan for Non-Employee Directors (which was depleted in 2019) as long as they remain a director of the Company; however, they may (a) sell up to 50% of an award to cover the tax obligation arising from such grant or grants and (b) make certain transfers of shares received under the 2004 Restricted Stock Plan for Non-Employee Directors to members of their immediate family or to a trust or other form of indirect ownership established by the director for his or her benefit or for the benefit of the members of his or her immediate family.
Shares for the purposes of determining compliance with our stock ownership policy are defined as Common Stock held outright (by the director or his or her spouse), restricted stock units, restricted stock awards, and shares or share equivalents held in a Company savings plan or deferred compensation plan. Stock options, stock appreciation rights, and PSUs are excluded from the definition of shares.
All directors currently comply with their respective ownership requirements or are retaining 50% of all net shares (post-tax) that vest until achieving their minimum share ownership requirement.
Deferred Director Fees
In December 2022, the Board adopted the 3D Systems Corporation Non-Employee Director Deferral Plan to allow non-employee directors to defer receipt of all or a portion of their equity compensation in a tax efficient manner.
Executive Compensation Matters
Compensation Discussion and Analysis
This Compensation Discussion and Analysis provides detailed information and analysis regarding the compensation of our named executive officers (“NEOs”) as reported in the “Summary Compensation Table” and the other tables located in this “Executive Compensation Matters” section.
Our Named Executive Officers for 2023
| Name | Title |
|---|---|
| Dr. Jeffrey A. Graves | President, Chief Executive Officer and Director |
| Jeffrey Creech(1) | Executive Vice President and Chief Financial Officer |
| Reji Puthenveetil | Executive Vice President, Additive Solutions and Chief Commercial Officer |
| Menno Ellis(2) | Executive Vice President, Health Care Solutions |
| Phyllis Nordstrom | Executive Vice President, Chief People Officer and Chief Administrative Officer |
| Andrew Johnson(3) | Executive Vice President, Chief Corporate Development Officer, Chief Legal Officer and Secretary and Former Interim Chief Financial Officer |
| Michael Turner(4) | Former Executive Vice President and Chief Financial Officer |
(1) Mr. Creech was appointed as the Company’s Executive President and Chief Financial Officer on December 13, 2023, succeeding Mr. Johnson, who served as the Company’s Interim Chief Financial Officer from October 16, 2023, to December 12, 2023.
(2) Mr. Ellis’s role and position with the Company were eliminated, effective April 30, 2024, as part of certain organizational changes in connection with the Company’s ongoing multi-faceted restructuring initiative.
(3) Mr. Johnson resigned his role and position within the Company, effective April 30, 2024, to pursue other career opportunities.
(4) Mr. Turner resigned as the Company’s Executive Vice President and Chief Financial Officer, effective October 15, 2023.
Compensation Considerations
Sound Pay Practices
Below we highlight certain of our key practices that we consider good governance features of our executive compensation program.
Executive Compensation Program Features
Executive Compensation Program Includes:
Maintain an Independent Compensation Committee — Our Compensation Committee consists solely of independent directors who establish our compensation practices.
Retain an Independent Compensation Advisor — Our Compensation Committee has engaged its own compensation consultant to provide information, analysis and other advice on executive compensation independent of management.
Stockholder Engagement — We regularly engage with our stockholders on our compensation program and implement enhancements based on feedback received.
Annual Executive Compensation Review — At least once a year, our Board conducts a review of our compensation strategy, and during fiscal year 2023, we did an in-depth review of our compensation program and updated our peer group for purposes of evaluating compensation and making compensation decisions for fiscal year 2023.
Limits on Maximum Payouts under Incentive Plans — In 2023, our annual bonus program was capped at 150% of target opportunity and our performance-share units were capped at 250% of target opportunity.
Transparent Disclosure of Incentive Plan Targets and Achievement — We disclose performance measures, metrics and results used to determine both annual bonuses and performance-share unit awards.
Compensation At-Risk — Our executive compensation program is designed so that a significant portion of the compensation of our executive officers is “at risk” based on corporate performance, to align the interests of our executive officers and stockholders. This “at risk” compensation included our annual bonus, restricted stock awards and performance-share units awarded in fiscal year 2023, which are discussed in additional detail below.
Stock Ownership Guidelines — We maintain minimum stock ownership guidelines and stock holding requirements applicable to our executive officers and the non-employee independent members of our Board. As of December 31, 2023, each of our executive officers had either satisfied such guidelines or had time remaining to do so under the guidelines.
Compensation Recovery (“Clawback”) Policy — In 2023, we adopted a new clawback policy that provides for recoupment of performance-based compensation in connection with restatements of financial results that reduce previously earned payouts, regardless of individual culpability, in compliance with the NYSE’s new rules.
Conduct an Annual Stockholder Advisory Vote on NEO Compensation — We conduct an annual stockholder advisory vote on the compensation of our NEOs. Our Board considers the results of this advisory vote during the course of its deliberations on executive compensation.
Compensation-Related Risk Assessment — We conduct regular risk assessments of our compensation programs and practices, and a full risk assessment was completed by our independent compensation consultant during fiscal year 2023 and reviewed by our Compensation Committee. We structure our executive compensation programs to try to minimize the risk of inappropriate risk-taking by our NEOs.
“Double-Trigger” Change in Control Arrangements.
Executive Compensation Program Does Not Include or Prohibits:
Guaranteed Bonuses — We do not provide guaranteed annual bonuses to our executive officers.
Defined Benefit Retirement Plans — We do not currently offer, nor do we have plans to offer, defined benefit pension plans or any non-qualified deferred compensation plans or arrangements to our NEOs other than arrangements that are available generally to all employees. Our NEOs are eligible to participate in our 401(k) retirement plan on the same basis as our other employees.
Hedging or Pledging of Company Securities — Our Policy Statement Governing Insider Trading prohibits any director, officer, employee or consultant of the Company from engaging in hedging activity and also prohibits any director or officer from holding Company securities in a margin account or pledging securities as collateral for a loan.
Excise Tax Gross-Ups — We do not offer our NEOs excise tax gross-ups on severance or change-in-control payments.
Stock Option Re-pricing— We do not permit options to purchase shares of our Common Stock to be repriced to a lower exercise price without the approval of our stockholders.
Compensation Philosophy
Our compensation philosophy is centered on pay for performance to drive long-term value for our stockholders. We believe that deep industry experience and technical knowledge is essential to our ability to innovate and provide full-service solutions to our customers and that the expertise of our executives and employees are critical factors to the Company’s success. The competition for talent across the industries in which we operate is intense, and we maintain focus on attracting, rewarding, and retaining a highly qualified executive team. Our executive compensation program and practices reflect the Board’s commitment to strong corporate governance and the recognition of achievements that create sustainable Company value.
We pursue this philosophy by designing our executive compensation program incorporating the following principles:
Alignment with long-term stockholders’ interests. We believe our executives’ interests are more directly aligned with our stockholders’ interests when compensation programs emphasize an appropriate balance of short- and long- term financial performance, are impacted by our stock price performance and require meaningful ownership of our stock.
Market competitive at target performance levels. We believe an executive’s total compensation should be competitive at the target performance level in order to attract qualified executives, motivate performance and retain, develop and reward executives with the abilities and skills needed to foster long-term value creation.
Achievement of financial goals and strategic objectives. We believe an effective way to create value over the long term is to make a significant portion of an executive’s overall compensation dependent on the achievement of our short- and long-term financial goals and strategic objectives and on the value of our stock.
Reward superior performance. We believe that although an executive’s total compensation should be tied to achievement of financial goals and strategic objectives and should be competitive at the target performance level, performance that exceeds target should be appropriately rewarded. We also believe there should be downside risk of below-target payouts if our financial performance is below target and if we do not achieve our financial goals and strategic objectives.
Incorporate evolving marketplace risks and trends. We believe that as our industry evolves and our opportunities for competitive business advantages change over time, we must likewise evolve in order to continue to create value. Our compensation programs must be tailored to our strategic priorities (which may require changing the performance measures in our incentive plans) and our current outlook (which may impact how we calibrate incentive plan payouts to various levels of performance).
The key elements of our compensation programs for our NEOs include:
Chief Executive Officer Reported Target Compensation vs. Realized + Realizable Compensation
A significant percentage of the compensation program of our NEOs, including our CEO, is performance-based and/or at-risk. The table below details differences between target total direct compensation and the sum of realized and realizable compensation for each of fiscal years 2021, 2022 and 2023. The information provided in the table below is intended to supplement, not replace, the information contained in the Summary Compensation Table regarding our CEO’s compensation for fiscal years 2021, 2022, and 2023, as presented and calculated in compliance with SEC rules.
| 2021 · 2022 · 2023 · 2021 - 2023 Total | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (A) · (B) · (A) · (B) · (A) · (B) · (A) · (B) | ||||||||||||
| Compensation Component | Target Total Direct Compensation | Realized + Realizable Compensation | (B) as a % of (A) | Target Total Direct Compensation | Realized + Realizable Compensation | (B) as a % of (A) | Target Total Direct Compensation | Realized + Realizable Compensation | (B) as a % of (A) | Target Total Direct Compensation | Realized + Realizable Compensation | (B) as a % of (A) |
| Salary | $837,400 | $837,400 | 100% | $849,800 | $849,800 | 100% | $849,800 | $849,800 | 100% | $2,537,000 | $2,537,000 | 100% |
| Short-Term Incentives | 849,800 | 1,274,697 | 150% | 850,000 | — | —% | 850,000 | — | —% | 2,549,800 | 1,274,697 | 50% |
| Long-Term Incentives | 6,378,697 | 2,259,670 | 35% | 4,765,861 | 875,715 | 18% | 5,268,229 | 1,201,693 | 23% | 16,412,787 | 4,337,078 | 26% |
| Total Direct Compensation | $8,065,897 | $4,371,767 | 54% | $6,465,661 | $1,725,515 | 27% | $6,968,029 | $2,051,493 | 29% | $21,499,587 | $8,148,775 | 38% |
The sum of realized and realizable compensation over these three years is only 38% of target total direct compensation, demonstrating the sensitivity of our compensation program to achievement of performance goals and its alignment with shareholder value creation.
For purposes of the above table, terms are defined as follows:
| Compensation Component | Target Total Direct Compensation | Realized Compensation | Realizable Compensation |
|---|---|---|---|
| Salary | As reported in each year’s Summary Compensation Table | As reported in each year’s Summary Compensation Table | — |
| Short-Term Incentives | Targeted amount, as reported under “Estimated Future Payouts Under Non-Equity Incentive Plan Awards” in each year’s Grant of Plan-Based Awards Table | Amounts actually paid, as reported in the “Non-Equity Incentive Plan Compensation” column in each year’s Summary Compensation Table | — |
| Long-term Incentives | The grant date fair value of awards, as reported in each year’s Summary Compensation Table | For Restricted Stock Awards granted in 2021, 2022 or 2023 that have vested as of 12/31/23, the number of shares vested multiplied by the closing price of our stock on the date of vesting | For Restricted Stock Awards granted in 2021, 2022 or 2023 that have not vested as of 12/31/23, the number of shares that have not yet vested multiplied by the closing price of our stock on 12/31/23 ($6.35).For PSUs granted in 2021, 2022 or 2023 that have not vested as of 12/31/23, the number of shares that would be earned if performance-based criteria were assessed as of 12/31/23 multiplied by our closing price on 12/31/23 ($6.35). |
Key Compensation Actions in 2023
Our Compensation Committee, which consists entirely of independent directors, sets the compensation of our NEOs. For 2023, the Compensation Committee took the following actions with respect to the compensation of our NEOs:
Reviewed the base salaries for our NEOs as part of our standard annual review cycle, maintaining flat salaries for all NEOs except Ms. Nordstrom, who received an increase in connection with the expansion of her responsibilities upon appointment as Chief People Officer and Chief Administrative Officer in December 2022. Mr. Creech was excluded from this annual review due to his December 2023 hire date; his employment agreement provides for a minimum base annual salary of $425,000, pro-rated for 2023.
Reviewed the 2023 Annual Bonus Program percentage of base salary targets for our NEOs, maintaining the target percentages from 2022 for all NEOs (100% of base salary for Dr. Graves and 60% of base salary for each of our NEOs except Mr. Creech, who did not participate in the fiscal 2023 Annual Bonus Program due to his December 2023 hire date).
Approved Annual Bonus Program metrics for 2023, weighting funding of the bonus program pool 50% towards revenue achievement and 50% towards adjusted EBITDA achievement for Dr. Graves and 40% towards revenue achievement, 40% towards adjusted EBITDA achievement and 20% towards individual goal achievement for each of our other NEOs, except Mr. Creech, who did not participate in the fiscal 2023 Annual Bonus Program due to his December 2023 hire date.
Awarded no bonus payout to any NEO under the 2023 Annual Bonus Program based on the Company’s 2023 performance against established revenue and adjusted EBITDA metrics. Mr. Turner was not eligible for a payout due to his October 2023 resignation date. Mr. Creech was not eligible for a payout due to his December 2023 hire date.
Approved Long-Term Incentive (“LTI”) compensation, consisting of a combination of restricted stock awards (50% weighting) and performance share unit awards (50% weighting) to provide strong links to long-term stockholder value creation and promote alignment with investors. Mr. Creech was excluded due to his December 2023 hire date.
Forfeiture of all Mr. Turner’s outstanding unvested equity awards, including restricted stock and PSUs upon his resignation in October 2023.
Awarded Mr. Johnson a one-time payment of $70,000 in December 2023 in connection with his service as Interim Chief Financial Officer from October 16, 2023, to December 12, 2023.
Entered into an employment agreement with Mr. Creech in connection with his appointment as Executive Vice President and Chief Financial Officer that provided for a base salary of $425,000 (pro-rated for 2023), a bonus objective of not less than 60% of Mr. Creech’s base salary beginning in 2024, and a time-based restricted stock award for a number of shares of our Common Stock calculated with a numerator equal to $500,000 and a denominator equal to the 20-trading day trailing average closing price of our Common Stock ended on December 12, 2023 that will vest in three equal annual installments during the continuation of Mr. Creech’s employment with the Company.
Compensation Consultant and Compensation Peer Group
For 2023, the Compensation Committee directly engaged Meridian Compensation Partners, LLC (“Meridian”) and considered its guidance in the establishment of the 2023 executive compensation program. Meridian provided no services to the Company other than to the Compensation Committee.
Based on its consideration of the various factors set forth in the rules promulgated by the SEC and the NYSE, the Compensation Committee has determined that the work performed by Meridian did not raise any conflict-of-interest concerns.
In August 2022, Meridian assisted the Compensation Committee in developing a peer group to serve as a market reference for establishing and evaluating the 2023 compensation programs for our NEOs. Our 2023 peer group was composed of 17 publicly traded, industry-specific companies. Companies selected were 0.5x to 2.0x our revenue and 0.4x to 4.0x our market capitalization at the time of selection. These companies were selected after the consideration of the following criteria:
quantitative criteria, including revenue size and growth, margins, market capitalization, headcount and R&D spend;
qualitative criteria, including service and product offerings and end markets served; and
likely competitors for executive talent
The 2023 peer group included:
| Altair Engineering | Globus Medical, Inc. (new addition) | Penumbra, Inc. (new addition) |
|---|---|---|
| AngioDynamics, Inc. (new addition) | LivaNova PLC | Proto Labs, Inc |
| Avid Technology | Mercury Systems, Inc. | Rogers Corporation |
| CONMED Corporation | Natus Medical Incorporated | Stratasys Ltd. |
| ESCO Technologies | Novanta Inc. | Tandem Diabetes Care |
| FARO Technologies, Inc. | NuVasive, Inc. (new addition) |
Relative to our 2022 peer group, four companies (ADTRAN Holdings, Inc., Extreme Networks, Inc., Veeco Instruments Inc. and Viavi Solutions Inc.) were removed to develop our 2023 peer group roster, in part to improve our alignment with the peer- group median for size and valuation statistics and in part to shift the peer group roster to include greater representation from companies serving healthcare end markets. At the time of selection, our 12-month trailing revenues approximated the 33 rd percentile relative to the 2023 peer group, while our 12-month average market capitalization approximated the 41 st percentile.
The Compensation Committee uses peer group data as a reference point (if available for a comparable position) and/or other compensation market data, including surveys such as the Radford Global Compensation Database. Relative to compensation market data, the Compensation Committee targets each element of executive compensation generally near the 50 th percentile. Variation in competitive positioning by executive will occur based on various factors including experience, the scope and complexity of the executive’s position relative to what is typical in the market, tenure, and other contributions.
Say-on-Pay
We provide stockholders with an advisory vote (“say-on-pay”) on the compensation of our NEOs. We currently hold this say-on-pay vote on an annual basis. Our say-on-pay proposal received support of more than 93% of votes cast at each of our last five Annual Meetings of Stockholders, including 96% at our 2023 Annual Meeting of Stockholders (“2023 Annual Meeting”). The Compensation Committee considered the stockholders’ strong support of our say-on-pay vote at the 2023 Annual Meeting when designing our executive compensation program. The Compensation Committee will consider the results of future advisory votes on executive compensation as our compensation philosophy continues to evolve and compensation decisions are made each year.
Determining Executive Compensation
The Compensation Committee is responsible for setting the compensation of all officers of the Company subject to Section 16 of the Exchange Act (“executive officers”) and each direct report of the CEO, including the NEOs.
The Compensation Committee reviews the CEO’s recommendation for each of the other NEO’s compensation during the first quarter of each year. The purpose of this annual review is:
to determine the amount of any annual incentive compensation to be awarded to each NEO for the preceding calendar year;
to determine any adjustments to be made to the annual salary of each NEO for the current year; and
to approve our incentive compensation program for the current year and establish target incentive compensation amounts for the current calendar year for each of the NEOs.
As part of this review, our CEO gives the Compensation Committee a recommendation for incentive compensation payouts for the prior year, salary adjustments for the current year, and target incentive compensation amounts for the current year for each of the other NEOs. These recommendations are developed using our market-based job architecture for all employees to ensure appropriate levels of pay at each employee classification across the Company. Our CEO uses the market-based job architecture and evaluation of each individual NEO’s contribution to strategic objectives to guide his compensation recommendations to the Compensation Committee. The Compensation Committee reviews those recommendations and modifies them to the extent it considers appropriate. As part of this process, the Compensation Committee approves the payout amount of any annual incentive compensation to be awarded to each individual with respect to the preceding calendar year, approves the amount of any adjustments to be made to the annual salary of each such individual for the current year, approves the terms of our incentive compensation program for the current calendar year, and establishes target incentive bonus and equity awards for the current year for each of our NEOs and each of the other individuals whose compensation it oversees. The Compensation Committee may also approve adjustments to compensation for specific individuals at other times during any year when there are significant changes in the responsibilities of such individuals or under other circumstances that the Compensation Committee considers appropriate.
Our CEO’s compensation is determined under similar principles but follows a different process designed to comply with applicable law and stock exchange listing requirements. After discussing the CEO’s self-evaluation with him and receiving the views of other independent directors, the Compensation Committee evaluates his performance and reviews that evaluation with him. Based on that evaluation and review, in conjunction with consideration of the Company’s performance (including stockholder returns) and competitive market data specific to our peer group as compiled by Meridian, the Compensation Committee determines his compensation and personal annual objectives for the coming calendar year. Our CEO is excused from meetings of the Compensation Committee and the independent members of the Board during voting or deliberations regarding his compensation.
While Meridian advised the Compensation Committee on the form and amount of compensation, the Compensation Committee (or the Board, in the case of the CEO) made all decisions regarding the compensation of our NEOs.
Elements of Executive Compensation
Our executive compensation program is designed to focus executive behavior on achievement of both our short- and long-term objectives and strategy to encourage the creation of sustainable, long-term value. We provide a mix of compensation elements that support our goals of attracting and retaining top executive talent and incentivizing key performance objectives for both the short and long term. The elements of executive compensation are designed to drive behavior that supports sustained stockholder return and pay-for-performance outcomes over time. To that end, our executive compensation program consists of the following principal elements:
annual base salaries;
when earned, incentive awards under our Annual Bonus Program; and
when earned, long-term equity compensation under our 2015 Incentive Plan.
Initial base salary and target annual bonus award levels and initial equity awards for new executives are negotiated with the individual during the search process and include consideration of prior compensation history, outstanding incentive awards that the new executive must abandon in order to join the Company, and benchmarking information and recommendations provided by the independent compensation consultant. Annual bonus compensation levels are standardized by title to promote internal parity.
In reviewing annual base salaries, target annual bonus awards, and annual long-term equity compensation targets, the Compensation Committee reviews each executive’s compensation history with the Company (including prior equity awards or grants), benchmarking information and recommendations provided by the independent compensation consultant, and internal parity. The Compensation Committee is guided by its own judgment and those sources of information (including, when deemed appropriate, compensation surveys) that the Compensation Committee considers relevant and the recommendations of its independent compensation consultant.
The Compensation Committee believes that the prudent use of judgement in determining compensation will generally be in our best interests and those of our stockholders. Accordingly, the Compensation Committee does not rely exclusively upon fixed formulas, and, from time to time in exercising its judgement, the Compensation Committee may approve changes in compensation that it considers to be appropriate to reward performance or otherwise to provide incentives toward achieving our objectives.
The Compensation Committee seeks to strike a balance that it considers to be appropriate in its discretion between fixed elements of compensation, such as base salaries, and variable performance-based elements represented by annual bonus awards and long-term equity compensation. As a general matter, the Compensation Committee believes that our NEOs should have at least one-third of their annual cash compensation opportunity at risk under variable performance-based elements of our incentive compensation program, including our Annual Bonus Program.
The charts below illustrate the relative weighting of our NEO compensation components at target in 2023. Dr. Graves’ compensation is displayed for “Components of CEO Compensation,” and the average of our other NEOs (excluding Mr. Creech, whose compensation package did not include all compensation elements for 2023) is displayed for “Components of Other NEO Compensation.”
Target Annual Bonus represents target opportunities for each NEO under the 2023 Annual Bonus Program. See “2023 Annual Bonus Program” for further details.
Performance Stock Units represents the grant date fair value of PSUs, which may be earned based on TSR performance over a three-year performance period.
Restricted Stock Awards represents the grant date fair value of time-based restricted stock, which vests ratably over three years.
A one-time payment of $70,000 to Mr. Johnson for his service as Interim Chief Financial Officer from October 16, 2023, to December 12, 2023, is excluded.
Base Salaries
Annual base salaries are intended to provide a base level of compensation to executives, including our NEOs, for serving as senior leaders of the Company and are aligned with the level of experience, capabilities, and scope of responsibilities of the executive. We pay annual salaries to provide executives a base level of compensation for services rendered during the year. Base salaries are also designed to help achieve our objectives of attracting and retaining executive talent. Adjustments to base salaries are based on the Company’s market-based job architecture, which takes into consideration the responsibilities of the executives, the Compensation Committee’s evaluation of the market demand for executives with similar capability and experience, and each individual NEO’s progress towards assigned strategic imperatives and concrete personal objectives.
2023 Salaries
The following table shows the 2023 annual base salary amounts for each NEO.
| Name | 2022 Year-End Base Salary | 2023 Year-End Base Salary($) | Aggregate % Increase |
|---|---|---|---|
| Jeffrey A. Graves | $850,000 | $850,000 | —% |
| Jeffrey Creech (1) | n/a | 425,000 | n/a |
| Reji Puthenveetil | 412,000 | 412,000 | —% |
| Menno Ellis | 412,000 | 412,000 | —% |
| Phyllis Nordstrom | 371,000 | 450,000 | 21.3% |
| Andrew M. Johnson | 400,000 | 400,000 | —% |
| Michael Turner (2) | 450,000 | n/a | n/a |
(1) Mr. Creech was appointed as the Company’s Executive Vice President and Chief Financial Officer on December 13, 2023.
(2) Mr. Turner resigned from the Company effective October 15, 2023.
The Compensation Committee maintained 2023 base salaries for all NEOs at the same levels in effect at the end of 2022, excepting Ms. Nordstrom, who received an increase in connection with the expansion of her responsibilities upon appointment as Chief People Officer and Chief Administrative Officer in December 2022.
Annual Bonus Program
Our Annual Bonus Program is designed to motivate our executives, including our NEOs, to achieve defined financial performance targets and, for NEOs other than Dr. Graves, individual achievement of strategic goals that are designed to position the Company as an industry leader. Both the defined financial performance targets and individual strategic goals are measured and evaluated on an annual basis.
This program is adopted annually and designed with our strategic objectives in mind. Under the Annual Bonus Program for Dr. Graves, 100% of our plan payouts are tied to the achievement of pre-determined corporate financial objectives established during the Company’s annual financial planning process. For other NEOs, 80% of our plan payouts are tied to the achievement of these same pre-determined corporate financial objectives while 20% are tied to the achievement of individual strategic goals established by Dr. Graves. The 20% weighting to the achievement of individual strategic goals is a new feature added in 2023.
Annual bonus awards are not guaranteed and are not awarded unless the pre-determined corporate financial objectives are achieved at pre-defined levels. Even if the pre-determined corporate financial objectives are achieved, our Compensation Committee retains discretion to reduce the funding of the Company-wide Annual Bonus Program pool or any individual participant’s award. This pay-for-performance plan aligns executive performance with the Company’s annual financial performance.
As an overriding condition, a failure to perform in accordance with our Code of Conduct or Code of Ethics may serve as a basis for a participant in this program not to receive a bonus payout. We consider this aspect of our Annual Bonus Program to be consistent with sound principles of corporate governance.
As part of its goal-setting process, the Compensation Committee establishes current-year target incentive awards for each NEO with the following principles in mind:
Targets are used to determine the amount of any annual bonus that our NEOs can expect to receive if we achieve our financial objectives and they achieve their individual strategic goals, as applicable, for the year in question. In setting these target bonus awards, the Compensation Committee considers each NEO’s level of responsibility, competitive market data and the recommendations of our CEO.
Target bonus awards are set at levels that are designed to link a substantial portion of each NEO’s total annual compensation opportunity to attaining the corporate objectives and individual strategic goals. Although generally higher, the Compensation Committee aims for at least one-third of each NEO’s annual cash compensation opportunity to be at risk. See “Grants of Plan-Based Awards in 2023” for a summary of target bonus awards for the NEOs applicable to 2023.
No minimum incentive awards are guaranteed to NEOs. The pool for the annual incentive plan is not funded unless the Company achieves certain pre-determined financial objectives.
Base target amounts represent the bonus awards that could be awarded assuming achievement of 100% of the pre-determined financial objectives and, as applicable, individual strategic goals.
Maximum amounts represent the maximum amount that may generally be awarded to each NEO under the program for the year in question. Our maximum annual incentive awards were equal to 150% of the target annual bonus awards for each of our NEOs during 2023.
Financial objectives are determined based upon our annual business plan for the year. This business plan is developed by management and approved by the Board of Directors. The Compensation Committee maintains the ability to adjust performance objectives for extraordinary items and other items as it deems appropriate based on pre-approved guidelines the Compensation Committee has set regarding the potential impact to performance objectives due to extraordinary transactions.
With respect to financial measures, 100% of each NEO’s bonus related to each financial measure would generally be deemed to have been earned if the target for that financial measure is fully achieved.
Due to his December 2023 hire date, Mr. Creech did not participate in the Annual Bonus Program for 2023.
2023 Annual Bonus Program
Consistent with the compensation philosophy, in February 2023, the Compensation Committee approved an annual bonus program for 2023 (the “2023 Annual Bonus Program”). The 2023 target bonus awards for each NEO were set at 60% of his or her 2023 base salaries, except for Dr. Graves, whose 2023 target incentive award was set at 100% of his 2023 base salary. The 2023 threshold and maximum annual bonus award for all NEOs were set at 50% and 150%, respectively, of the target annual bonus award.
The Compensation Committee approved the following performance objectives, selected to reflect the Company’s focus on top-line revenue growth and alignment with investor focus and strategic business plan priorities, for the funding of the 2023 Annual Bonus Program:
40% of the funding of the 2023 Annual Bonus Program (50% for Dr. Graves) was based on actual achievement relative to our annual revenue budget;
40% of the funding of the 2023 Annual Bonus Program (50% for Dr. Graves) was based on actual achievement relative to our annual budgeted level of adjusted EBITDA; and
20% of the funding of the 2023 Annual Bonus Program (0% for Dr. Graves) was based on actual achievement relative to individual strategic goals.
Adjusted EBITDA is a non-GAAP measure defined as net income, plus income tax (provision)/benefit, interest and other income/(expense), net, stock-based compensation expense, amortization of intangibles, depreciation expense and other non-recurring and/or non-cash items.
Revenue and adjusted EBITDA objectives are independent of each other and could be earned irrespective of achievement of the other objective. The Compensation Committee established threshold, target and maximum performance goals for each of these financial measures under the 2023 Annual Bonus Program in February 2023. Our target performance for each of these financial measures for 2023 were consistent with the Company’s consolidated budget approved by the Board. The table below sets forth the specific financial performance goals and related payout factors established by the Compensation Committee under the 2023 Annual Bonus Program.
| Performance Goals for 2023(1) · Payout Factor (% of Target Bonus)(2) | ||||
|---|---|---|---|---|
| Achievement Levels | Revenue($) | Adjusted EBITDA($) | CEO | Other NEOs |
| Maximum | ≥ 617.0 | ≥ 8.6 | 150% | 150% x 80% weighting = 120% |
| Target | 560.9 | 4.3 | 100% | 100% x 80% weighting = 80% |
| Threshold | 504.8 | 0 | 50% | 50% x 80% weighting = 40% |
| Below Threshold | < 504.8 | < 0.0 | —% | 0% x 80% weighting = 0% |
(1) All performance goals are expressed in millions.
(2) Payouts for performance between the stated achievement are calculated using linear interpolation.
For 2023 individual strategic goals specific to each NEO other than Dr. Graves, there were only three possible payout options. The table below sets the payout factors approved by the Compensation Committee under the 2023 Annual Bonus Program.
| Achievement Levels Relative to Individual Strategic Goals | Payout Factor (% of Target Bonus) |
|---|---|
| Exceeds | 150% x 20% weighting = 30% |
| Meets | 100% x 20% weighting = 20% |
| Inconsistent | 25% x 20% weighting = 5% |
| Below Inconsistent | 0% x 20% weighting = 0% |
No payout is possible relative to individual strategic goals if there is no payout for financial performance goals.
Our performance under the 2023 Annual Bonus Program fell below threshold for both revenue and adjusted EBITDA. Therefore, the Compensation Committee determined no payout should be made to any NEO under the 2023 Annual Bonus Program irrespective of achievement by an NEO of his or her individual strategic goals.
| Performance Goal · Performance Achieved($) · Payout Factor · Weighting · Payout Earned(% of Target Bonus) | ||||||
|---|---|---|---|---|---|---|
| CEO · Other NEOs · CEO · Other NEOs | ||||||
| Revenue | 488.1 million | —% | 50% | 40% | —% | —% |
| Adjusted EBITDA | <0.0 | —% | 50% | 40% | —% | —% |
| Individual Strategic Goals | Irrelevant due to Below Threshold Financial Achievement | —% | —% | 20% | —% | —% |
| Total | —% | —% | ||||
Long-Term Equity Compensation
Our long-term equity compensation program is designed to attract, retain and motivate our executives, including our NEOs, and to align their interests with those of our stockholders and the Company’s long-term strategic objectives. Our equity program is a key component in our strategy to hire and retain top talent in a highly competitive environment.
The Compensation Committee administers our 2015 Incentive Plan. Under that plan, the Compensation Committee is authorized to grant restricted stock awards, restricted stock units (“RSUs”), stock options, stock appreciation rights and other awards that are provided for under the 2015 Incentive Plan to our employees and the employees of our subsidiaries as the Compensation Committee determines to be eligible for awards. Awards granted to a participant are based upon a number of factors, including the recipient’s position, salary and performance, as well as our overall corporate performance.
The 2015 Incentive Plan is intended to provide an effective method of motivating performance from key employees, including our NEOs, and for creating an alignment of interests in participants with the interests of our stockholders. Awards are made under the 2015 Incentive Plan as long-term incentive compensation to NEOs and other key employees when the Compensation Committee believes such awards are appropriate. The Compensation Committee makes awards both to reward performance and to motivate the recipient’s long-term performance. In order to continue providing meaningful long-term incentives to NEOs and employees, we routinely look to replenish shares available under the 2015 Incentive Plan.
Long-Term Incentive Compensation Program
The Compensation Committee divides long-term equity grants for executives equally between restricted stock awards with time-based vesting conditions and PSUs. Time based awards are used to drive retention of executive talent, while PSUs drive alignment of executive realized compensation with long-term stockholder value. The PSUs typically are granted in the first quarter of the performance year upon completion of the budgeting process to support the selection of appropriate performance targets. Historically, PSU awards can only be earned by the NEOs upon our achievement of pre-determined levels of financial performance.
In determining 2023 LTI target award amounts, the Compensation Committee considered corporate performance, competitive market data for each individual, the level of the individual’s responsibility, prior compensation and retentive impact of that prior compensation and individual contributions to the Company.
The values below are the target long-term equity compensation amounts approved by the Compensation Committee for each of our NEOs, which are then converted into a number of shares of a combination of restricted stock and target PSUs using an approved formula based on stock price. For the accounting grant date fair value of such awards, see the “Summary Compensation Table” below.
| Awards in Shares | |||
|---|---|---|---|
| Name | 2023 LTI Award at Target(1) | Performance Stock Units(50% weighting)($10.28 conversion price(2)) | Restricted Stock Awards (50% weighting)($10.04 conversion price(3)) |
| Jeffrey A. Graves | $3,800,000 | $184,824 | $189,243 |
| Jeffrey Creech | — | — | — |
| Reji Puthenveetil | 1,350,000 | 65,661 | 67,231 |
| Menno Ellis | 1,350,000 | 65,661 | 67,231 |
| Phyllis Nordstrom | 1,000,000 | 48,638 | 49,800 |
| Andrew Johnson | 1,000,000 | 48,638 | 49,800 |
| Michael Turner | 1,500,000 | 72,957 | 74,701 |
(1) See “2023 Long-Term Incentive Awards” for further details on these 2023 LTI awards.
(2) Conversion price of $10.28 represents the average closing price of our Common Stock for the 60 trading days ending March 31, 2023. The 2023 LTI awards had different calculation periods in order to facilitate the measurement of the PSUs to end at a quarter end on March 31, 2026.
(3) Conversion price of $10.04 represents the average closing price of our Common Stock for the 20 trading days ending April 13, 2023.
Mr. Turner forfeited all outstanding unvested equity awards, including restricted stock and PSUs, upon his resignation in October 2023.
Mr. Creech did not receive a 2023 LTI award but under the terms of his employment agreement on December 13, 2023, was awarded 94,696 shares of time-based restricted stock, with the size of the award calculated using a numerator equal to $500,000 and a denominator equal to the 20-trading day trailing average closing price of the Company’s Common Stock ended on December 12, 2023, or $5.28.
Mr. Johnson forfeited all outstanding unvested equity awards, including restricted stock and PSUs, upon his resignation on April 30, 2024. Upon Mr. Ellis’s separation from the Company on April 30, 2024, Mr. Ellis forfeited all outstanding unvested equity awards, including restricted stock and PSUs.
Long-Term Equity Features
Restricted stock awards and PSU awards issued pursuant to the 2015 Incentive Plan remain subject to forfeiture until the vesting of such shares pursuant to the terms of the applicable award.
Shares of restricted stock and PSUs issued pursuant to the 2015 Incentive Plan may not be sold, transferred, or encumbered by the employee before they vest or are earned, as applicable. The compensation associated with these awards is expensed over the vesting period. The shares covered by restricted stock awards are considered outstanding upon issuance following the acceptance of each award for the purpose of calculating diluted earnings per common share, and holders of shares issued pursuant to restricted stock awards are entitled to vote such shares and to receive any dividends declared in respect of our Common Stock upon vesting of the award shares. Shares covered by PSUs are not considered outstanding until vested except for the purpose of calculating diluted earnings per common share. The holders of PSUs are not entitled to vote shares or receive any dividends declared with respect to the shares covered by such awards.
2023 Long-Term Incentive Awards
In February 2023, the Compensation Committee made LTI awards of restricted stock and PSUs under the 2015 Incentive Plan to executives, including the NEOs, to reflect the contributions that those individuals have made to our operations and financial condition, to provide motivation toward achieving our future strategic objectives and to further align the interests of those individuals with our stockholders. Restricted stock awards vest ratably over three years on each anniversary of the date of grant, subject to continued employment. The PSUs only vest if both performance and service-based criteria are met.
The Compensation Committee approved the use of relative total stockholder return (“TSR”) as the performance objective for the 2023 PSUs awarded to our NEOs. This market-based measure reflects the desire to focus executives on the execution of the Company’s long-term strategic objective of increasing stockholder value. TSR will be assessed relative to the Total 3D Printing Index published by Solactive (Bloomberg Ticker: 3DPRNT Index) (“3DPRNT”). The Company’s TSR will be calculated by subtracting the beginning stock price of $10.28 (i.e., the average closing price of the Company’s Common Stock over the 60 trading days ending March 31, 2023) from the ending stock price (i.e., the average closing price of the Company’s Common Stock over the 60 trading days ending on March 31, 2026), adding any dividends paid during the period for the performance period from April 1, 2023 through March 31, 2026, and then dividing the result by the Company’s beginning stock price. Similarly, 3DPRNT’s TSR will be calculated by subtracting the 3DPRNT beginning stock price of $109.22 (i.e., the average closing price of 3DPRNT’s stock price over the 60 trading days immediately prior to April 1, 2023, as reported in U.S. dollars on Bloomberg) from the 3DPRNT ending stock price (i.e., the average closing price of 3DPRNT’s stock price over the 60 trading days ending on March 31, 2026, as reported in U.S. dollars on Bloomberg) for the performance period of April 1, 2023 to March 31, 2026, adding any dividends during the period, and then dividing the result by the 3DPRNT beginning stock price. The target PSUs will be adjusted for performance between 0% and 250% based on the comparison of the TSR of the Company relative to the TSR of 3DPRNT during the performance period as follows:
| Achievement | Company TSR –3DPRNT TSR = | Example: if Company TSR is 50%, 3DPRNT TSR Must be… | Performance Adjusting |
|---|---|---|---|
| Below Threshold | More than 25 Percentage Points below 0 OR Company TSR is negative | More than 75% | —% |
| Threshold | 25 Percentage Points Below 0 | 75% | 50% |
| Target | 0 Percentage Points | 50% | 100% |
| Midpoint of Target and Maximum | 50 Percentage Points | —% | 200% |
| Maximum | 100 Percentage Points | (50)% | 250% |
At the end of the performance period, if the performance-based criteria are met, all PSUs earned will convert into immediately vested stock.
In April 2026, the Compensation Committee will certify performance under the 2023 PSUs and determine, within a range of 0-250% of target, the number of shares earned.
Employment Agreements and Other Agreements with NEOs
The Company entered into employment agreements with each of our NEOs. Each of these agreements was determined based on negotiations with the applicable NEO and took into account his or her background and qualifications and the nature of his or her position. We believe that these compensation packages are appropriate in light of the intense competition for top executives in our industry and among similarly situated companies, and that the terms of these arrangements are consistent with our executive compensation goals, including the balancing of short-term and long-term compensation to properly motivate our NEOs.
Our employment agreements with each of Dr. Graves, Messrs. Creech, Puthenveetil, Ellis, Johnson and Turner and Ms. Nordstrom provide for an initial two-year employment term that automatically extends for additional one-year periods unless terminated by the NEO or us upon at least 30 days’ prior written notice of intention not to renew. The agreements may also be terminated by us or the NEO for other reasons and, subject to the conditions set forth in the employment agreements, provide for certain payments and benefits in connection with certain termination events or a change of control as described under “Potential Benefits upon Termination or Change of Control” below.
Dr. Jeffrey A. Graves
Dr. Graves’ employment agreement provides for a minimum base annual salary of $825,000 and a target bonus opportunity equal to 100% of his base salary, with the exact amount of any such bonus to be based upon the achievement of performance goals to be determined by the Compensation Committee. The employment agreement entitles Dr. Graves to participate in all other benefits generally available to our other executive employees, including participation in the Company’s health benefit plans and equity award programs. Pursuant to Dr. Graves’ employment agreement he was granted the following initial equity awards:
a restricted stock award for shares of Common Stock with a value of $2,000,000 that vested 20%, 40%, and 40% on December 31, 2020, December 31, 2021, and December 31, 2023, respectively, and
a long-term equity grant with a value of $2,500,00 equally divided between a time-based restricted stock award that vested in three equal annual installments on each of the first, second, and third anniversaries of May 26, 2020, the date of grant, and a PSU award, which may be earned during the three-year period ending on May 26, 2023 based on the achievement at threshold (25%), target (50%), and maximum (75%) TSR, which would earn 50%, 100%, and 150% of the PSU, respectively, subject to his continued employment.
Dr. Graves’ employment agreement automatically extended for an additional one-year period in May 2023.
Jeffrey Creech
Mr. Creech’s employment agreement provides for a minimum base annual salary of $425,000 and a target bonus opportunity of not less than 60% of his base salary, with the exact amount of any such bonus to be based upon the achievement of performance goals to be determined by the Compensation Committee. The employment agreement entitles Mr. Creech to participate in all other benefits generally available to our other executive employees, including participation in the Company’s health benefit plans and equity award programs. Pursuant to Mr. Creech’s employment agreement he was granted the following equity award:
a time-based restricted stock award for shares of Common Stock with a value of $500,000 that is scheduled to vest in three equal annual installments on each of the first, second and third anniversaries of December 13, 2023, the date of grant, subject to his continued employment.
Reji Puthenveetil
Mr. Puthenveetil’s employment agreement provides for a minimum base annual salary of $400,000 and a target bonus opportunity of not less than 50% of his base salary, with the exact amount of any such bonus to be based upon the achievement of performance goals to be determined by the Compensation Committee. The employment agreement entitles Mr. Puthenveetil to participate in all other benefits generally available to our other executive employees, including participation in the Company’s health benefit plans and equity award programs. Pursuant to Mr. Puthenveetil’s employment agreement he was granted the following initial equity awards:
a long-term equity grant with a value of $1,000,00 equally divided between a time-based restricted stock award, that vests in three equal annual installments on each of the first, second and third anniversaries of October 1, 2020, and a PSU award, which may be earned during the three-year period ending on October 1, 2023 based on the achievement at threshold (25%), target (50%), and maximum (75%) TSR, which would earn 50%, 100%, and 150% of the PSU, respectively, and
a 2021 long-term equity award for shares of Common Stock with a value equal to $1,000,000, equally divided between time-based restricted stock and PSU, issued pursuant to the service and performance criteria set by the Compensation Committee as part of its 2021 executive compensation program.
Mr. Puthenveetil’s employment agreement automatically extended for an additional one-year period in October 2023.
Menno Ellis
Mr. Ellis’ employment agreement provides for a minimum base annual salary of $330,000. Mr. Ellis is also entitled to receive cash performance bonuses, with the exact amount of any such bonus to be based upon the achievement of performance goals to be determined by the Compensation Committee. The employment agreement entitles Mr. Ellis to participate in all other benefits generally available to our other executive employees, including participation in the Company’s health benefit plans and equity award programs. His agreement also provides that his primary work location will be his home office in Dallas, Texas.
Mr. Ellis’ employment agreement automatically extended for an additional one-year period in November 2023.
Mr. Ellis’s role and position within the Company were eliminated, effective April 30, 2024. In connection with his departure
Mr. Ellis received (i) a severance payment in the amount of $412,000, and (ii) Company-paid monthly premium payments for COBRA health and dental insurance coverage such that Mr. Ellis’ contributions to such plans remain the same as if he were employed by the Company until the earlier of (1) 12 months following his separation date and (2) the date Mr. Ellis is no longer eligible for COBRA coverage. Mr. Ellis forfeited all outstanding unvested equity awards, including restricted stock and PSUs, upon his separation. Mr. Ellis continues to provide executive transition consulting services to the Company at the rate of $375 per hour (plus expenses) under a Consulting Agreement dated May 1, 2024 with The Kaminda Group, an entity controlled by Mr. Ellis.
Phyllis Nordstrom
Ms. Nordstrom’s employment agreement provides for a minimum base annual salary of $350,000 and a target bonus opportunity of not less than 60% of her base salary, with the exact amount of any such bonus to be based upon the achievement of performance goals to be determined by the Compensation Committee. The employment agreement entitles Ms. Nordstrom to participate in all other benefits generally available to our other executive employees, including participation in the Company’s health benefit plans and equity award programs. Pursuant to Ms. Nordstrom’s employment agreement she was granted the following equity awards:
a time-based restricted stock award for shares of Common Stock with a value of $500,000 that vests in three equal annual installments on each of the first, second and third anniversaries of August 30, 2021, the date of grant, subject to her continued employment; and
a time-based restricted stock award for shares of Common Stock with a value of $100,000 which vested and became exercisable in full on the first anniversary of August 30, 2021, the date of grant.
Ms. Nordstrom’s employment agreement provides for the guarantee of Ms. Nordstrom’s 2021 Performance Bonus at its target amount and pro-rated based on the Effective Date. It also provides that the Company shall provide or reimburse Ms. Nordstrom for certain expenses relating to her relocation to the Charlotte, North Carolina metro area, in accordance with Company’s US Domestic Relocation Policy and consistent with the Company’s relocation benefits for executives.
Ms. Nordstrom’s employment agreement automatically extended for a one-year period in August 2023.
Andrew M. Johnson
Mr. Johnson’s employment agreement provides for a minimum base annual salary of $333,000. Mr. Johnson is also entitled to receive cash performance bonuses, with the exact amount of any such bonus to be based upon the achievement of performance goals to be determined by the Compensation Committee. The employment agreement entitles Mr. Johnson to participate in all other benefits generally available to our other executive employees, including participation in the Company’s health benefit plans and equity award programs.
Mr. Johnson’s employment agreement automatically extended for an additional one-year period in June 2023.
Mr. Johnson resigned from his role and position within the Company, effective April 30, 2024. In connection with this resignation, Mr. Johnson received (i) a severance amount equal to $400,000, paid in 12 monthly installments following his separation date, (ii) Company-paid monthly premium payments for COBRA health and dental insurance coverage such that Mr. Johnson’s contributions to such plans remain the same as if he were employed by the Company until the earlier of (1) 12 months following the Separation Date and (2) the date Mr. Johnson is no longer eligible for COBRA coverage, and (iii) a one-time $300,000 cash retention bonus. Mr. Johnson forfeited all outstanding unvested equity awards, including restricted stock and PSUs, upon his resignation on April 30, 2024. Mr. Johnson continues to provide executive transition consulting services to the Company at the rate of $250 per hour (plus expenses) under a Consulting Agreement dated May 1, 2024.
Michael Turner
Mr. Turner’s employment agreement provided for a minimum base annual salary of $450,000 and a target bonus opportunity of not less than 60% of his base salary, with the exact amount of any such bonus to be based upon the achievement of performance goals to be determined by the Compensation Committee. The employment agreement entitled Mr. Turner to participate in all other benefits generally available to our other executive employees, including participation in the Company’s health benefit plans and equity award programs. Pursuant to Mr. Turner’s employment agreement he was granted the following equity awards:
a signing bonus of $225,000, provided that he was not terminated for cause within the first 24 months of his employment with the Company, and
a time-based restricted stock award for shares of Common Stock with a value of $1,500,000 that scheduled to vest in three equal annual installments on each of the first, second and third anniversaries of August 29, 2023, the date of grant, subject to his continued employment.
On September 18, 2023, Mr. Turner notified the Company of his resignation as Executive Vice President and Chief Financial Officer of the Company, effective October 15, 2023. In connection with his departure, Mr. Turner forfeited his participation in the fiscal 2023 Annual Bonus Program and all outstanding unvested equity awards, including restricted stock and PSU. Mr. Turner retained his signing bonus on his departure as consideration for ongoing consulting services to the Company.
Change of Control Severance Policy
On February 22, 2018, the Compensation Committee adopted the Company’s Change of Control Severance Policy (the “COC Severance Policy”). The COC Severance Policy is intended to provide eligible officers with reasonable financial security in their employment and position with the Company without distraction from uncertainties regarding their employment created by the possibility of a potential or actual change of control. The COC Severance Policy applies to our CEO and all Executive Vice Presidents and Senior Vice Presidents, which includes all our NEOs. For a more detailed discussion of the benefits payable to our NEOs under the COC Severance Policy, see “Potential Benefits upon Termination or Change of Control” below.
Other Compensation Matters
Benefits and Perquisites
We provide our employees, including the NEOs, with a benefit program that we believe is reasonable, competitive, and consistent with the objectives of our compensation program. As a matter of policy, the Compensation Committee does not award personal benefits or perquisites to our NEOs that are unrelated to our business and strives to mitigate the use of non-performance-based forms of compensation. However, under certain circumstances, the Compensation Committee has approved certain personal benefits or perquisites that are either provided to a NEO by contract or that it deemed to be in our interests to induce executives to commence or maintain employment with us. Those amounts are reported in the “Summary Compensation Table” below.
Our executives, including the NEOs, are eligible to participate in employee benefit programs that we provide to our employees generally, which include a group insurance program providing group health, dental, vision, life and long-term disability insurance. Other benefits include a Section 401(k) plan, health savings accounts, flexible spending accounts for health and dependent care expenses, sick leave, holiday time, and vacation time. Our NEOs are eligible for a comprehensive annual executive physical, a benefit that is capped at $5,000 annually.
We also reimburse certain commuting expenses for executives. For Mr. Puthenveetil, these commuting expenses included rent reimbursement for temporary housing in Rock Hill, South Carolina, certain past mileage expenses and a tax gross-up for federal, state and other income taxes resulting from imputed income relating to these commuting expenses.
For Ms. Nordstrom, these commuting expenses included airfare between Minneapolis, Minnesota and Charlotte, North Carolina, lodging, and car rental charges and a tax-gross up for federal, state and other income taxes resulting from imputed income related to these commuting expenses.
We also maintain an employee relocation policy, offering different tiers of benefits based on job level, for employees who are requested to relocate their primary residence in connection with their employment. For a further discussion, see Note 5 to the “Summary Compensation Table” below. Relocation assistance is necessary to induce executives to join the Company.
We believe the cost of providing perquisites in 2023 was reasonable and represents a relatively small percentage of each NEO’s overall compensation package.
Executive Stock Ownership Guidelines
Our executive officers and certain other senior members of management are required to maintain a minimum equity stake in the Company. This policy reflects the Board’s belief that our most senior executives should maintain a significant personal financial stake in the Company to promote long-term stockholder value. In addition, the policy helps align executive and stockholder interests, which reduces the incentive for excessive short-term risk taking. Each of our NEOs and certain other senior officers are required to acquire and maintain ownership of shares of our Common Stock equal to a specified multiple of his or her base salary, as shown in the table below. Each officer subject to a share ownership requirement must retain 50% of all net shares (post-tax) that vest until achieving his or her minimum share ownership requirement.
| Title | Minimum Stock Ownership Requirement |
|---|---|
| Chief Executive Officer | 6x annual base salary |
| Chief Financial Officer | 3x annual base salary |
| Other Executive Officers (EVPs) | 2x annual base salary |
| Other Senior Officers (SVPs) | 1x annual base salary |
Shares owned for the purposes of determining compliance with our stock ownership policy are defined as shares of Common Stock held outright (by the executive or his/her spouse), restricted stock units, restricted stock awards, and shares or share equivalents held in a Company savings plan or deferred compensation plan. Stock options, stock appreciation rights, and PSUs are excluded from the definition of shares owned.
All NEOs currently comply with their respective ownership requirements or are retaining 50% of all net shares (post-tax) that vest until achieving their minimum share ownership requirement. Our NEOs are expected to achieve the required stock-ownership levels within five years from the time they are appointed to or promoted to an executive position of Senior Vice President or higher.
Policy on Hedging and Transactions
Our Policy Statement Governing Insider Trading (the “Insider Trading Policy”) prohibits any director, officer, employee, or consultant of the Company or any of its subsidiaries or affiliates from engaging in short-term or speculative transactions in our securities. This policy includes within its coverage short sales, which for directors and executive officers of the Company are prohibited by Section 16 of the Exchange Act. It also prohibits transactions in publicly traded options, such as puts, calls, and other derivative securities, or purchase financial investments (including prepaid variable forward contracts, equity sweeps, collars, and exchange funds), or the engagement in transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of our Common Stock.
The Insider Trading Policy also prohibits any director or executive officer from holding Company securities in a margin account or pledging (or hypothecating) Company securities as collateral for a loan.
The Insider Trading Policy requires that our directors and executive officers pre-clear any transactions in our securities with our Chief Legal Officer or Assistant General Counsel.
Clawbacks of Incentive Compensation
Each of our NEOs is subject to our clawback policy. In response to the SEC’s adoption of final clawback rules and the NYSE’s publication of corresponding listing standards, the Board recently amended and restated our clawback policy to comply with final stock exchange listing standards, effective October 2, 2023.
Under the terms of this policy, following an accounting restatement of the Company’s financial statements, due to material noncompliance with any financial reporting requirement under securities laws, the Board or an appropriate Board committee must clawback any “excess compensation” received by an executive officer (current or former) during the applicable look-back period regardless of whether the executive officer engaged in misconduct or was otherwise directly or indirectly responsible for the accounting restatement. The Company will not indemnify any executive officer against the loss of any excess compensation as a result of the application of the clawback policy.
The Company will disclose publicly recoupment of any excessive compensation pursuant to this policy.
Risk Assessment of Compensation Policies and Practices
Our Compensation Committee has reviewed our incentive compensation programs, discussed the concept of risk
as it relates to our compensation program, considered various mitigating factors, and reviewed these items with its independent consultant, Meridian Compensation Partners, LLC (“Meridian”). In addition, our Compensation Committee asked Meridian to conduct an independent risk assessment of our executive compensation program. Based on these reviews and discussions, the Compensation Committee does not believe our compensation program creates risks that are reasonably likely to have a material adverse effect on our business.
Compensation Committee Report
The Compensation Committee has reviewed and discussed with management the section titled “Compensation Discussion and Analysis” found in this Item 11. Based on such review and discussion, the Compensation Committee has recommended to the Board of Directors that such section be included in this Form 10-K.
Compensation Committee:
Kevin S. Moore, Chair
Malissia Clinton
William E. Curran
Thomas Erickson
Jim D. Kever
Compensation Committee Interlocks and Insider Participation
None of our current executive officers served during 2023 as a director of any entity with which any of our outside directors is associated or whose executive officers served as one of our directors, and none of the members of the Compensation Committee has been an officer or employee of the Company or any of our subsidiaries.
Compensation Tables and Narratives
Summary Compensation Table
The following table presents information regarding the compensation of each of the NEOs for services rendered during 2023, 2022, and 2021
| Name and Principal Position (1) | Year | Salary (2) | Bonus (3) | Stock Awards (4) | Option Awards | Non-Equity Incentive Plan Compensation | All Other Compensation (5) | Total |
|---|---|---|---|---|---|---|---|---|
| ($) · ($) · ($) · ($) · ($) · ($) · ($) | ||||||||
| Jeffrey Graves | 2023 | 849,800 | — | 5,268,229 | — | — | 417,601 | 6,535,630 |
| President and Chief Executive Officer | 2022 | 849,800 | — | 4,765,861 | — | — | 71,501 | 5,687,162 |
| 2021 | 837,400 | — | 6,378,697 | — | 1,274,697 | 83,434 | 8,574,228 | |
| — | ||||||||
| Jeffrey Creech | 2023 | 13,077 | — | 589,956 | — | — | — | 603,033 |
| Executive Vice President and Chief Financial Officer | — | |||||||
| — | ||||||||
| Reji Puthenveetil | 2023 | 412,000 | — | 1,871,604 | — | — | 28,512 | 2,312,116 |
| Executive Vice President - Additive Solutions and Chief Commercial Officer | 2022 | 412,000 | — | 1,693,130 | — | — | 59,643 | 2,164,773 |
| 2021 | 406,000 | — | 2,319,545 | — | 370,792 | 38,687 | 3,135,024 | |
| — | ||||||||
| Menno Ellis | 2023 | 412,000 | — | 1,871,604 | — | — | 8,469 | 2,292,073 |
| Executive Vice President, Health Care Solutions | 2022 | 412,000 | — | 1,693,130 | — | — | 3,191 | 2,108,321 |
| 2021 | 406,000 | — | 2,319,545 | — | 370,792 | 8,400 | 3,104,737 | |
| — | ||||||||
| Phyllis Nordstrom | 2023 | 428,731 | — | 1,386,371 | — | — | 281,638 | 2,096,740 |
| Executive Vice President, Chief People Officer and Chief Administrative Officer | — | |||||||
| — | ||||||||
| Andrew Johnson | 2023 | 470,000 | — | 1,386,371 | — | — | 8,400 | 1,864,771 |
| Executive Vice President, Chief Corporate Development Officer, Chief Legal Counsel, and Interim Chief Financial Officer | 2022 | 396,042 | 100,000 | 1,128,725 | — | — | 8,400 | 1,633,167 |
| 2021 | 379,650 | — | 2,251,252 | — | 346,761 | 8,400 | 2,986,063 | |
| — | ||||||||
| Michael Turner | 2023 | 363,461 | — | 699,948 | — | — | 4,795 | 1,068,204 |
| Former Executive Vice President and Chief Financial Officer | 2022 | 147,115 | 225,000 | 1,322,155 | — | — | — | 1,694,270 |
(1) This column includes the name and principal position of each NEO during the fiscal year ended December 31, 2023.
(2) The amounts in the salary column represent the salary paid to each NEO with respect to each year during which he or she was a NEO.
(3) No bonuses were awarded to our NEOs in 2023.
(4) The amounts reported in this column for 2023 represent the aggregate grant date fair value computed in accordance with ASC Topic 718 of restricted stock awards and PSU awards. The value of restricted stock awards is determined by multiplying the number of shares awarded by the closing price of our Common Stock on the date of grant. The value of the PSU awards, which have a market-based performance metric and a three-year performance period, was determined using a Monte Carlo simulation technique under the option pricing method assuming target performance. For these PSUs, achievement of the highest level of performance conditions would result in the NEOs receiving 250% of the target amounts. These amounts are: Dr. Graves, $8,737,555; Mr. Puthenveetil, $3,104,124; Mr. Ellis, $3,104,124; Ms. Nordstrom, $2,299,361; Mr. Johnson, $2,299,361; and Mr. Turner, $3,449,042. See “2023 Long-Term Incentive Awards” above.
(5) The amounts shown for 2023 in the “All Other Compensation” column are composed of the following components:
| Name | 401K Match | Relocation Expenses | Rent and Travel Expenses | Relocation, Rent and Travel Expenses Tax Gross Up | Total All Other Compensation |
|---|---|---|---|---|---|
| Jeffrey Graves | $8,400 | $221,582 | $— | $187,619 | $417,601 |
| Jeffrey Creech | — | — | — | — | — |
| Reji Puthenveetil | 4,200 | — | 18,420 | 5,892 | 28,512 |
| Menno Ellis | 8,469 | — | — | — | 8,469 |
| Phyllis Nordstrom | 8,400 | 150,000 | 39,627 | 83,611 | 281,638 |
| Andrew Johnson | 8,400 | — | — | — | 8,400 |
| Michael Turner | 4,795 | — | — | — | 4,795 |
Mr. Graves relocation expenses relate primarily to reimbursement of commission expenses in connection with selling the home where he lived prior to joining the Company in 2020. Mr. Puthenveetil’s rent expenses relate to the reimbursement of lease payments for an apartment near the Company’s headquarters in Rock Hill, South Carolina. Ms. Nordstrom’s relocation expenses relate to a lump sum payment made in 2023 in connection with Ms. Nordstrom’s planned relocation to the Rock Hill, South Carolina area. In each case, the Company agreed to provide a gross up amount to the executive for tax planning purposes.
Grants of Plan-Based Awards in 2023
The following table sets forth information with respect to plan-based awards granted in 2023. The threshold, target, and maximum amounts represent the incentive awards for the 2023 Annual Bonus Program and the PSUs that could be awarded assuming achievement of the pre-determined performance metric over the three-year performance period (such achievement to be certified by the Compensation Committee subsequent to the completion of the performance period). No annual bonus award payouts were earned by the NEOs with respect to 2023 Annual Bonus Program.
For further details about our employment agreements with our NEOs, see “Employment Agreements and Other Agreements with NEOs.”
| Estimated Future Payouts Under Non-Equity Incentive Plan Awards · Estimated Future Payments Under Equity Incentive Plan Awards (1) · All Other Stock Awards: Number of Shares or Units · Grant Date Fair Value of Stock and Option Awards (2) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Threshold · Base Target · Maximum · Threshold · Base Target · Maximum | ||||||||||
| Name | Program | Grant Date | ($) | ($) | ($) | (#) | (#) | (#) | (#) | (#) |
| Dr. Jeffrey Graves | 2023 Bonus Program | 2/22/2023 | $425,000 | $850,000 | $1,275,000 | |||||
| 2023 LTI RSAs | 4/14/2023 | 189,243 | 1,773,207 | |||||||
| 2023 LTI Performance Shares | 4/3/2023 | 92,412 | 184,824 | 462,060 | 3,495,022 | |||||
| Jeffrey Creech | New Hire Award | 12/13/2023 | 94,696 | 589,956 | ||||||
| Reji Puthenveetil | 2023 Bonus Program | 2/22/2023 | 123,600 | 247,200 | 370,800 | |||||
| 2023 LTI RSAs | 4/14/2023 | 67,231 | 629,954 | |||||||
| 2023 LTI Performance Shares | 4/3/2023 | 32,831 | 65,661 | 164,153 | 1,241,650 | |||||
| Menno Ellis | 2023 Bonus Program | 2/22/2023 | 123,600 | 247,200 | 370,800 | |||||
| 2023 LTI RSAs | 4/14/2023 | 67,231 | 629,954 | |||||||
| 2023 LTI Performance Shares | 4/3/2023 | 32,831 | 65,661 | 164,153 | 1,241,650 | |||||
| Phyllis Nordstrom | 2023 Bonus Program | 2/22/2023 | 135,000 | 270,000 | 405,000 | |||||
| 2023 LTI RSAs | 4/14/2023 | 49,800 | 466,626 | |||||||
| 2023 LTI Performance Shares | 4/3/2023 | 24,319 | 48,638 | 121,595 | 919,745 | |||||
| Andrew Johnson | 2023 Bonus Program | 2/22/2023 | 120,000 | 240,000 | 360,000 | |||||
| 2023 LTI RSAs | 4/14/2023 | 49,800 | 466,626 | |||||||
| 2023 LTI Performance Shares | 4/3/2023 | 24,319 | 48,638 | 121,595 | 919,745 | |||||
| Michael Turner (3) | 2023 Bonus Program | 2/22/2023 | 135,000 | 270,000 | 405,000 | |||||
| 2023 LTI RSAs | 4/14/2023 | 74,701 | 699,948 | |||||||
| 2023 LTI Performance Shares | 4/3/2023 | 36,479 | 72,957 | 182,393 | 1,379,617 | |||||
(1) The amounts in these columns represent PSUs that vest in full on or about April 3, 2026, based on achievement of TSR over a three-year performance period.
(2) The amounts included in the “Grant Date Fair Value of Stock and Option Awards” column represent the aggregate grant date fair value computed in accordance with ASC Topic 718.
(3) Mr. Turner resigned from the Company effective October 15, 2023. In connection with his departure, Mr. Turner forfeited his participation in the 2023 Annual Bonus Program and all outstanding unvested equity awards.
Outstanding Equity Awards at Year-End 2023
The following table presents information with respect to equity awards made to each of our NEOs that were outstanding on December 31, 2023.
| Option Awards · Stock Awards | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| EquityIncentivePlanAwards:Number of Securities Underlying Unexercised Unearned Options (1) · Option Exercise Price · Option Expiration Date · Number of Shares or Units of Stock That Have Not Vested · Market Value of Shares or Units of Stock That Have Not Vested (2) · Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested · Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested (2) | ||||||||||
| Name · Grant Date · (#) · ($) · (#) · ($) · (#) · ($) | ||||||||||
| Jeffrey Graves | 1/12/2021 | — | — | — | 35,248 | (3) | 223,825 | — | — | |
| 1/12/2021 | — | — | — | — | — | 158,622 | (6) | 1,007,250 | ||
| 3/15/2022 | — | — | — | 76,582 | (4) | 486,296 | — | — | ||
| 4/1/2022 | — | — | — | — | — | 110,144 | (6) | 699,414 | ||
| 4/3/2023 | — | — | — | 184,824 | (6) | 1,173,632 | ||||
| 4/14/2023 | — | — | — | 189,243 | 1,201,693 | — | — | |||
| Jeffrey Creech | 12/13/2023 | — | — | — | 94,696 | (5) | 601,320 | — | — | |
| Reji Puthenveetil | 1/12/2021 | — | — | — | 12,818 | (3) | 81,394 | — | — | |
| 1/12/2021 | — | — | — | — | — | 57,681 | (6) | 366,274 | ||
| 3/15/2022 | — | — | — | 27,206 | (4) | 172,758 | — | — | ||
| 4/1/2022 | — | — | — | — | — | 39,130 | (6) | 248,476 | ||
| 4/3/2023 | — | — | — | 65,661 | (6) | 416,947 | ||||
| 4/14/2023 | — | — | — | 67,231 | (5) | 426,917 | — | — | ||
| Menno Ellis | 12/1/2016 | 100,000 | 13 | 12/1/2026 | — | — | — | — | ||
| 12/1/2016 | — | — | — | — | — | 20,000 | (7) | 127,000 | ||
| 1/12/2021 | — | — | — | 12,818 | (3) | 81,394 | — | — | ||
| 1/12/2021 | — | — | — | — | — | 57,681 | (6) | 366,274 | ||
| 3/15/2022 | — | — | — | 27,206 | (4) | 172,758 | — | — | ||
| 4/1/2022 | — | — | — | — | — | 39,130 | (6) | 248,476 | ||
| 4/3/2023 | — | — | — | 65,661 | (6) | 416,947 | ||||
| 4/14/2023 | — | — | — | 67,231 | (5) | 426,917 | — | — | ||
| Phyllis Nordstrom | 8/30/2021 | — | — | — | 5,685 | (3) | 36,100 | — | — | |
| 3/15/2022 | — | — | — | 15,114 | (3) | 95,974 | — | — | ||
| 4/1/2022 | — | — | — | 21,739 | (6) | 138,043 | ||||
| 12/2/2022 | — | — | — | 7,114 | (3) | 45,174 | — | — | ||
| 4/3/2023 | — | — | — | 48,638 | (6) | 308,851 | ||||
| 4/14/2023 | — | — | — | 49,800 | (5) | 316,230 | — | — | ||
| Andrew Johnson | 7/26/2016 | 160,000 | 13 | 7/26/2026 | — | — | — | — | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 7/26/2016 | — | — | — | — | — | 40,000 | (7) | 254,000 | ||
| 1/12/2021 | — | — | — | 10,894 | (3) | 69,177 | — | — | ||
| 1/12/2021 | — | — | — | — | — | 49,029 | (6) | 311,334 | ||
| 3/15/2022 | — | — | — | 18,137 | (4) | 115,170 | — | — | ||
| 4/1/2022 | — | — | — | — | — | 26,086 | (6) | 165,646 | ||
| 4/3/2023 | — | — | — | 48,638 | (6) | 308,851 | ||||
| 4/14/2023 | — | — | — | 49,800 | (5) | 316,230 | — | — | ||
| Michael Turner | 8/29/2022 | — | — | — | 85,910 | (4) | 545,529 | — | — | |
| 4/3/2023 | — | — | — | 72,957 | (6) | 463,277 | ||||
| 4/14/2023 | — | — | — | 74,701 | (5) | 474,351 | — | — | ||
(1) Option awards in this column vest upon the satisfaction of certain share price performance conditions.
(2) Value calculated based on the $6.35 closing price of our common stock on December 29, 2023.
(3) The outstanding balance of this award vests on the third anniversary of the grant date.
(4) The outstanding balance of this award vests in equal installments on the second and third anniversary of the grant date.
(5) Award vests in equal installments over a three-year period on the first, second and third anniversaries of the grant date.
(6) Amount represents the number of performance-based restricted stock unit awards based on achievement of target performance over a 3-year performance period other than those with January 12, 2021, grant dates, which are shown at maximum, in each case based on performance against the relevant metrics during 2023.
(7) Restricted stock awards that vest upon the satisfaction of certain share price and financial performance conditions.
Option Exercises and Stock Vested in 2023
No options were exercised by our NEOs in 2023. Shares of restricted Common Stock and RSUs held by the NEOs vested as follows during 2023:
| Number of Shares Acquired on Vesting | Value Realized on Vesting (1) | |
|---|---|---|
| Name | (#) | ($) |
| Jeffrey Graves | 385,331 | $3,307,565 |
| Jeffrey Creech | — | — |
| Reji Puthenveetil | 196,394 | 975,941 |
| Menno Ellis | 39,232 | 395,646 |
| Phyllis Nordstrom | 26,381 | 224,997 |
| Andrew Johnson | 30,040 | 307,770 |
| Michael Turner | 42,955 | 263,314 |
(1) Amounts reflect aggregate market value of our Common Stock based on the closing price of our Common Stock on the applicable vesting date.
Potential Benefits Upon Termination or Change in Control
Graves Employment Agreement
Under his employment agreement, Dr. Graves would, upon termination by the Company without “cause” or resignation for “constructive discharge” (in each case as defined in his agreement), become entitled to receive the following:
An amount equal to 150% of his base salary, payable in 18 equal monthly installments;
Any accrued but unpaid base salary as of the termination date;
Any accrued but unused vacation time;
Any accrued but unpaid performance bonus as of the termination date, on the same terms and at the same times as would have applied had his employment not terminated; and
If he elects COBRA coverage for health and/or dental insurance, Company-paid monthly premium payments for such coverage such that his contributions to such plans will remain the same as if he was employed by the Company until the earliest of: (1) 18 months from the termination date or (2) the date he is no longer eligible for COBRA coverage.
In the event of termination by the Company without “cause” or resignation for “constructive discharge” within 180 days before or two years after a “change of control” (as defined in his employment agreement), Dr. Graves is entitled to receive a lump sum cash payment equal to: (i) two times the sum of his base salary and target annual bonus, (ii) a pro rata portion of his target annual bonus for the fiscal year in which the termination occurs, (iii) accelerated vesting of the unvested shares under all outstanding time-based equity award and conversion of outstanding PSUs into immediately accelerated restricted stock awards (“RSAs”), and (vi) the difference between the monthly COBRA rate and the active employee premium rate for the applicable group health coverage (i.e., medical, dental and vision) for 24 months.
Creech, Puthenveetil, Ellis, Nordstrom, Johnson and Turner Employment Agreements
Under their employment agreements, Messrs. Creech, Puthenveetil, Ellis, Johnson and Turner and Ms. Nordstrom would, upon termination by the Company without “cause” or resignation for “constructive discharge” (in each case as defined in their respective agreements), become entitled to receive the following:
An amount equal to the NEO’s base salary, payable in 12 equal monthly installments;
Any accrued but unpaid base salary as of the termination date;
Any accrued but unpaid performance bonus as of the termination date, on the same terms and at the same times as would have applied had the NEO’s employment not terminated; and
If the NEO elects COBRA coverage for health and/or dental insurance, Company-paid monthly premium payments for such coverage such that the NEO’s contributions to such plans will remain the same as if the NEO were employed by the Company until the earliest of: (1) 12 months from the termination date; or (2) the date the NEO is no longer eligible for COBRA coverage.
On September 18, 2023, Mr. Turner notified the Company of his voluntary resignation effective October 15, 2023. In connection with his resignation, Mr. Turner received no special benefits.
Mr. Johnson resigned from his role and position within the Company, effective April 30, 2024. In connection with his resignation, Mr. Johnson received (i) a severance amount equal to $400,000, paid in 12 monthly installments following his separation date, (ii) Company-paid monthly premium payments for COBRA health and dental insurance coverage such that Mr. Johnson’s contributions to such plans remain the same as if he were employed by the Company until the earlier of (1) 12 months following the Separation Date and (2) the date Mr. Johnson is no longer eligible for COBRA coverage, and (iii) a one-time $300,000 cash retention bonus. Mr. Johnson forfeited all outstanding unvested equity awards, including restricted stock and PSUs, upon his resignation on April 30, 2024. Mr. Johnson continues to provide executive transition consulting services to the Company at the rate of $250 per hour (plus expenses) under a Consulting Agreement dated May 1, 2024.
Mr. Ellis’s role and position within the Company were eliminated, effective April 30, 2024. In connection with his departure from the Company, Mr. Ellis received (i) a severance payment in the amount of $412,000, and (ii) Company-paid monthly premium payments for COBRA health and dental insurance coverage such that Mr. Ellis’ contributions to such plans remain the same as if he were employed by the Company until the earlier of (1) 12 months following his separation date and (2) the date Mr. Ellis is no longer eligible for COBRA coverage. Mr. Ellis forfeited all outstanding unvested equity awards, including restricted stock and PSUs, upon his separation. Mr. Ellis continues to provide executive transition consulting services to the Company at the rate of $375 per hour (plus expenses) under a Consulting Agreement dated May 1, 2024 with The Kaminda Group, an entity controlled by Mr. Ellis.
See “Change of Control Severance Policy” for a description of payments to be received by these NEOs upon a termination in connection with a change of control.
Change of Control Severance Policy
On February 22, 2018, the Compensation Committee adopted the Company’s the COC Severance Policy. The COC Severance Policy is intended to provide eligible officers with reasonable financial security in their employment and position with the Company, without distraction from uncertainties regarding their employment created by the possibility of a potential or actual change of control. The COC Severance Policy applies to our CEO and all Executive Vice Presidents and Senior Vice Presidents (each, a “Participant”), which includes all of our NEOs.
A Participant is entitled to benefits under the COC Severance Policy in the event of a termination of the Participant’s employment by the Company without “Cause” or by the Participant for “Constructive Discharge” either (a) on or before the second anniversary of the date of a “Change of Control” (as such terms are defined in the COC Severance Policy) or (b) in certain circumstances, within six months prior to the date that the Change of Control occurs (a “Qualifying Termination”). The COC Severance Policy does not change the terms of any plans or arrangements that may provide for severance benefits in case of a termination of employment not in connection with a Change of Control. The COC Severance Policy also includes provisions intended to avoid duplication of benefits with the severance benefits that otherwise may be payable under any other plan or arrangement upon a Qualifying Termination.
In the event of a Qualifying Termination, a Participant will receive a lump sum cash payment equal to: (i) a multiple (which is 2.0 for our CEO and 1.5 for all other Participants) times the sum of the Participant’s base salary and target annual bonus, (ii) a pro rata portion of the Participant’s target annual bonus for the fiscal year in which the termination occurs, and (iii) the difference between the monthly COBRA rate and the active employee premium rate for the applicable group health coverage (i.e., medical, dental and vision) as elected by the Participant (for the Participant and his or her eligible dependents) at the time of the Qualifying Termination multiplied by a number of months equal to 24 for our CEO and 18 for each other Participant. A Participant’s right to receive this payment and benefits is subject to his or her execution of a general release of claims against the Company. In addition, the COC Severance Policy provides that all outstanding performance-based equity awards granted after the effective date of the COC Severance Policy shall be converted in their entirety to timed-based equity awards upon the occurrence of a Change of Control based on the assumption that the performance goals are achieved at target. The vesting of performance-based equity awards that are converted to time-based equity awards shall occur upon the same vesting schedule upon which the former performance metrics would have been measured and shall vest in full upon a Qualifying Termination. Additionally, if a Participant incurs a Qualifying Termination, all outstanding time-based awards equity awards, including converted performance-based equity awards that are held by a Participant and were granted after the effective date of the COC Severance Policy shall become fully vested and all forfeiture restrictions shall lapse.
The following table reflects the amount of compensation that would be paid to each of our NEOs in the event of a termination of the executive officer’s employment under various scenarios. The amounts shown assume that such termination was effective as of December 31, 2023, and include estimates of the amounts that would be paid to each executive officer upon such NEO’s termination. The table only includes additional benefits that result from the termination and does not include any amounts or benefits earned, vested, accrued or owing under any plan for any other reason. None of our NEOs is entitled to any additional benefits in connection with a Change of Control without a related termination of employment.
| Name (1) | Without Cause or Good Reason (not in Connection with a Change in Control) (2) | Death or Disability (3) | Termination in Connection with a Change in Control (4) |
|---|---|---|---|
| Jeffrey Graves | $1,294,122 | $— | $8,217,606 |
| Jeffrey Creech | 425,000 | — | 1,621,320 |
| Reji Puthenveetil | 426,629 | — | 2,723,510 |
| Menno Ellis | 430,381 | — | 2,729,138 |
| Phyllis Nordstrom | 504,546 | — | 2,048,041 |
| Andrew Johnson | 418,446 | — | 2,274,078 |
(1) None of the NEOs will receive any special benefits in the event of voluntary separation without good reason or termination for cause. Under standard plan provisions, the NEOs will continue to be eligible for benefits under the Company’s medical and dental plans until the last day of the month in which termination occurs. Any bonus earned in the year of termination is forfeited.
(2) Amounts in this column represent the cash and benefits to be paid to the NEO in the event of termination by the Company without cause or resignation with good reason (each as defined in the NEO’s employment agreement). For Dr. Graves the severance benefits represent (i) 18 months of base salary and (ii) COBRA reimbursement for 18 months. For Messrs. Creech, Puthenveetil, Ellis, and Johnson and Ms. Nordstrom, severance benefits represent: (i) 12 months of base salary and (ii) COBRA reimbursement for 12 months. Mr. Creech was not yet enrolled in health benefits as of December 31, 2023.
(3) Amounts in this column represent the bonus for the year of termination that each NEO would have received in the event of termination by death or disability.
(4) The amounts in this row are payable in the event of termination by the Company without cause or resignation for “constructive discharge” within six months prior to or two years after a “change of control.” Certain amounts are duplicative of amounts payable in the event of termination by the Company without cause or resignation for “constructive discharge” not in connection with a change of control. For Dr. Graves the severance benefits represent (i) two times the sum of (x) the NEO’s then-current base salary and (y) the NEO’s target cash incentive bonus amount, (ii) payment of the bonus earned under the Annual Bonus Program, (iii) accelerated vesting of the unvested shares under outstanding time-based RSA awards (301,073 shares), (iv) the conversion of outstanding PSUs into immediately-accelerated RSAs (payout assumed at target share amount of 453,590 shares), and (v) COBRA reimbursement for 24 months.
For Messrs. Creech, Puthenveetil, Ellis, and Johnson, severance benefits represent: (i) two times the sum of (x) the NEO’s then-current base salary and (y) the NEO’s target cash incentive bonus amount, (ii) accelerated vesting of the unvested shares under outstanding time-based RSA awards (94,696, 107,255, 107,255 and 78,831 shares, respectively), (iii) the conversion of outstanding PSUs into immediately-accelerated RSAs (payout assumed at target share amount of 0, 162,472, 182,472 and 163,753 shares, respectively), and (iv) COBRA reimbursement for 18 months.
For Mr. Nordstrom, severance benefits represent: (i) two times the sum of (x) her then-current base salary and (y) her target cash incentive bonus amount, (ii) accelerated vesting of the unvested shares under outstanding time-based RSA awards (77,713 shares), (iii) the conversion of outstanding PSUs into immediately-accelerated RSAs (payout assumed at target share amount of 70,377 shares), and (iv) COBRA reimbursement for 18 months. In each case, the value of accelerated equity amounts was computed based on the closing price of our Common Stock on December 29, 2023, of $6.35.
CEO Pay Ratio
As required by applicable SEC rules, we must annually disclose the annual total compensation of our median employee (excluding the CEO), the annual total compensation of our CEO, and the ratio of the CEO compensation to the median employee compensation.
For 2023, our last completed fiscal year:
the annual total compensation of our CEO, calculated from information reported in the Summary Compensation Table included elsewhere in this Item 11, was $6,535,630; and
the annual total compensation of our median employee (excluding our CEO) was $80,353.
Based on this information, for 2023 the ratio of the annual total compensation of our CEO to the annual total compensation of our median employee was 81 to 1.
We identified our median employee in 2023 using a multistep process and took the following steps to determine the annual total compensation of that employee and our CEO for 2023:
We determined that, as of December 31, 2023, our active, global employee population consisted of approximately 1,923 individuals (excluding the CEO). This population consisted of our full-time, part-time, and temporary employees employed with us as of that date.
To identify the median employee from our employee population, we used annual base salary as of December 31, 2023.
For the annual total compensation of our median employee, we identified and calculated the elements of that employee’s compensation for 2023 in accordance with the requirements of Item 402(c)(2)(x), which are the same requirements we used to determine the annual total compensation of our CEO.
The CEO pay ratio reported is a reasonable estimate calculated in a manner consistent with SEC rules based on the methodologies and assumptions described. SEC rules for identifying the median employee and determining the CEO pay ratio permit companies to employ a wide range of methodologies, estimates and assumptions. As a result, the CEO pay ratios reported by other companies, which may have employed other permitted methodologies or assumptions and which may have a significantly different work force structure from ours, are likely not comparable to our CEO pay ratio.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.